Evaluating lymph node metastases in esophageal cancer after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the distribution of lymph node metastases in patients with esophageal carcinoma following transthoracic esophagectomy with at least a 2-field lymphadenectomy. It will include patients with resectable esophageal or gastro-esophageal junction carcinoma from multiple centers across 18 countries over a period of approximately 7 years. The study will also evaluate the accuracy of preoperative diagnostics and the prognostic value of different lymph node stations, as well as overall and disease-free survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Primary squamous cell or adenocarcinoma of the esophagus or esophago-gastric junction
* Surgically resectable (cT1-4a, N0-3, M0)
* Adequate physical condition to undergo transthoracic surgery (ASA 1-3)
* Transthoracic esophagectomy

Exclusion Criteria:

* Previous thoracic or abdominal (upper GI) surgery disturbing lymph drainage of the esophagus and stomach
* Patients with in situ carcinoma or high grade dysplasia

Where it's running

• MD Anderson Cancer Center
  Houston, Texas, United States Recruiting
• Instituto Nacional de Câncer
  Rio de Janeiro, Brazil Recruiting
• University of Toronto
  Toronto, Canada Recruiting
• Fudan University Shanghai Cancer Center
  Shanghai, Yangpu, China Recruiting
• Hospital District of Helsinki and Uusimaa
  Helsinki, Finland Recruiting
• University Medical Center of the Johannes Gutenberg University
  Mainz, Germany Recruiting

Study contacts

• Principal investigator: Mark I van Berge Henegouwen, MD, PHD — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Study coordinator: Suzanne S Gisbertz, MD, PhD
• Email: s.s.gisbertz@amc.nl
• Phone: +31205669111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proximal versus total gastrectomy for locally advanced Siewert type II–III gastroesophageal junction cancer

  This will see if keeping part of the stomach (proximal gastrectomy) or removing the whole stomach (total gastrectomy) leads to better 3-year disease-free survival for adults with locally advanced Siewert type II–III gastroesophageal junction cancer.

  Recruiting Bakirkoy Dr. Sadi Konuk Research and Training Hospital · Istanbul, Istanbul · NCT07482566

• Omega-3 supplements with PD-1 therapy for advanced esophageal cancer

  This trial will test whether taking omega-3 fish oil (EPA+DHA) together with PD-1 immunotherapy helps adults with recurrent or metastatic esophageal cancer maintain muscle and have better clinical and patient-reported outcomes than a placebo.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07272382

• LY4337713 for people with FAP-positive ovarian, breast, pancreatic, colorectal, or esophageal cancers

  This trial tests LY4337713, a FAP-targeted lutetium-177 therapy, in people with advanced cancers that show high levels of fibroblast activation protein (FAP).

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Newport Beach, California and 29 other locations · NCT07213791

• LY4257496 for GRPR-positive advanced breast, colorectal, prostate, and endometrial cancer (OMNIRAY)

  This Phase 1 test tries LY4257496, with GRPR imaging using LY4257529 and sometimes standard treatments, to see if it is safe and helps people with GRPR-positive advanced breast, colorectal, prostate, or endometrial cancer.

  Recruiting at 15 sites Phase 1 Eli Lilly and Company · Duarte, California and 32 other locations · NCT07114601

• High-sensitivity blood test to detect and monitor multiple cancers

  This study will test a high-sensitivity blood test that looks for tumor DNA to detect and follow several common cancers in adults with those cancers or people having routine health screenings.

  Recruiting Yonsei University · Seoul · NCT07035587

• Combining Fruquintinib and Tislelizumab with Radiotherapy for Esophageal Cancer

  This study is testing if combining two new cancer treatments, Fruquintinib and Tislelizumab, with radiation can help people with advanced esophageal cancer feel better and improve their outcomes.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT06646588

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.